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Abstract: Hepatocarcinogenesis is a complex process that remains still partly understood. 
That might be explained by the multiplicity of etiologic factors, the genetic/epigenetic 
heterogeneity of tumors bulks and the ignorance of the liver cell types that give rise to 
tumorigenic cells that have stem cell-like properties. The DNA stress induced by 
hepatocyte turnover, inflammation and maybe early oncogenic pathway activation and 
sometimes viral factors, leads to DNA damage response which activates the key tumor 
suppressive checkpoints p53/p21
Cip1 and p16
INK4a/pRb responsible of cell cycle arrest and 
cellular senescence as reflected by the cirrhosis stage. Still obscure mechanisms, but 
maybe involving the Wnt signaling and Twist proteins, would allow pre-senescent 
hepatocytes to bypass senescence, acquire immortality by telomerase reactivation and get 
the last genetic/epigenetic hits necessary for cancerous transformation. Among some of the 
oncogenic pathways that might play key driving roles in hepatocarcinogenesis, c-myc and 
the Wnt/-catenin signaling seem of particular interest. Finally, antiproliferative and 
apoptosis deficiencies involving TGF-, Akt/PTEN, IGF2 pathways for instance are 
prerequisite for cancerous transformation. Of evidence, not only the transformed liver cell 
per se but the facilitating microenvironment is of fundamental importance for tumor bulk 
growth and metastasis. 
Keywords: hepatocellular carcinoma; stem cells; cellular stress; senescence; oncogenes; 
tumor suppressors 
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1. Introduction 
Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide, developing 
mainly in cirrhosis. Hepatitis B (HBV) or C virus (HCV) chronic infections account for 75% of HCCs 
whereas nonviral etiologies as alcohol, genetic or metabolic disorders represent less than 25% of cases. 
Furthermore, western countries suffer from a substantial and constant increase of HCC incidence due 
to HCV infection. Dramatically, HCC is a poor prognosis tumor, and is the first cause of death in 
cirrhotic patients. Current therapies are rather inefficient, mainly due to usually late diagnosis and high 
recurrence rates within the remaining cirrhotic liver after surgical resection [1-3].  
Hepatocarcinogenesis is tightly linked to chronic liver damage, and rarely develops in healthy liver. 
That might be due to the possible requirement of chronic inflammation and cell divisions in a context 
of cellular stress which lead towards the step-wise acquisition of genetic and epigenetic hits necessary 
for cellular transformation. In addition, the virus persistence per se can trigger deregulation of the 
cellular machinery. By contrast to HCV, HBV can integrate into the host genome, leading to genomic 
instability, rearrangements and more rarely cis- or trans- activation of proto-oncogenes. Although the 
direct involvement of viral proteins in hepatocarcinogenesis is not clear, it seems that HBx and Pre-S2 
for HBV as well as core and others for HCV can interact with and deregulate cellular machinery. 
However, data was obtained from in vitro transfection assays or in vivo transgenic mouse models. 
Nevertheless, these models support supra-natural viral protein expression levels, and nothing is known 
about these interplays in a context of natural viral infection [4-6].  
Herein we will aim to describe the general mechanisms which could be involved in 
hepatocarcinogenesis independently of etiologic factors underlying the chronic liver disease.  
2. Tumor Bulk and Cancer Stem Cell Concept 
The most common and unifying condition associated with hepatocarcinogenesis is cirrhosis, which 
develops after long latencies (20-40 years) of chronic liver disease. HCC risk remains low during 
chronic liver disease but dramatically increases at the cirrhotic stage. Hepatocarcinogenesis remains 
partly obscure. Initially, a variety of genetic and epigenetic alterations have been detected in human 
and experimental HCCs. Later on, DNA microarray analysis has led to an extensive integrative 
approach, leading to identification of clusters of HCCs that allow comparison between phenotypes in 
experimental and human HCCs, and may predict outcome of patients. However, none of the identified 
genes is universally expressed by tumor cells that are heterogeneous in their morphology, clinical 
behaviour, and molecular profiles in the tumor bulk [7-9]. These observations lead to the suspicion that 
the current studies might have focused only on the heterogeneous “end products” – i.e. “adult” tumor 
cells within the tumor bulk - but not the “root” cell (Figure 1) [10-13]. More interestingly, molecular 
signatures from cirrhotic nonneoplastic tissues can predict occurrence/reccurrence of HCC [14], letting 
hypothesize that although “root” cells exist within the heterogeneous “end product” tumor bulk, they 
also might be present in cirrhotic tissues prone to develop HCC.  Viruses 2009, 1                                       
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Figure 1. The cancer stem cells (CSC) model. Proposed hierarchical organization of a 
malignant clone. CSC have self-renew and tumorigenic capacities. They can give rise to 
more and more differentiated cancerous cells which the last ones in the hierarchical 
organization may have low or absent proliferative capabilities (1). During asymetric 
division at self-renew, the original CSC can give birth to the identical CSC (2) that will 
lead to the same tumor clone (grey), or can give birth to a genetically/epigenetically 
modified CSC (3) that will lead to a more aggressive tumor clone (black) with 
differentiation blockage and higher proliferative capabilities. To date, it is not clear 
whether the more differentiated cells can revert back and regain a more stem cell 
properties. As appreciated from the definition of a CSC, this cell is not necessarily derived 
from a normal tissue stem cell. Alternatively, hypothetical genetic/epigenetic changes 
caused in more committed and differentiated cancerous cells might be very well involved 
in mechanisms allowing these cells to acquire cancer stem cell capabilities.  
 
(1)   
(2)  
CSC 
CSC
CSC
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Tumors originate from normal cells as a result of accumulated genetic/epigenetic changes. It was 
initially believed that cancers arose exclusively by de-differentiation of mature cells, and tumor cell 
heterogeneity could be explained by the clonal evolution model [15]. More recent findings suggest that 
heterogeneity may come from derivation of endogenous progenitor/stem cells or de-differentiation of a 
transformed cell [16-17]. This hypothesis supports an early proposal that cancers represent “blocked 
ontogeny” and a derivative that cancers are transformed stem cells (Figure 1). The normal liver has Viruses 2009, 1                                       
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tissue-determined stem cells and ductal bipotent committed progenitors that are scarce and not brought 
into play except with the occurrence of both liver injury and inhibition of proliferation of mature 
hepatocytes. These latter are not terminally differentiated and can respond to injury by highly 
regulated proliferation. Although the cell type giving rise to HCC has been shown as dependent on 
many factors in experimental hepatocarcinogenesis, few is known in humans. One can speculate that 
“root” cells might come from the neoplastic transformation of different normal liver cell types: 
periductal stem cells, bipolar ductal committed progenitor cells, or differentiated hepatocytes. Thus, it 
would not be surprising to find HCC as arising differentially from one (or several) of them, depending 
on extrinsic factors such as viral infection, or deregulation of intrinsic key pathways [18-23]. The 
maturation arrest of cells at various stages of differentiation in a hierarchical cell lineage may best 
explain the various types of human liver cancer. From analysis of established HCCs, we might 
speculate that HCCs contain cancer stem cells (CSC) – i.e. cells with stem-cell-like properties of 
immortality, resistance to therapy, and transplantability. As hepatocarcinogenesis is likely a dynamic 
process leading from a normal cell towards an initiated root cell and thereafter a hugely heterogeneous 
tumor bulk, abnormalities useful for initiation of root cells are not mandatory found in all cancerous 
cells forming the tumor bulk. In addition, abnormalities found in tumor bulks might evolve with time 
and/or under pressure of anti-cancer therapies, thus strengthening the need of cautious when 
interpreting a molecular profile. However, some fundamental events have been described as key steps 
in cellular transformation and very likely necessary and sufficient to allow each cell to get and keep 
the cancerous phenotype.  
3. Oncogenic Stress and Cellular Behaviour 
Cancer cells contain multiple genetic/epigenetic alterations, and chromosomal aberrations. It has 
been rationalized that a long period of time is required for any individual cell to accumulate the right 
combination of alterations that promote the cancer cell phenotype. Alterations consistently found in 
cancer cells are selected because they confer a growth advantage by either activating growth 
promoting pathways, inactivating growth inhibitory cascades or allowing alterations to accumulate 
[24]. Over the life span any individual cell can acquire multiple alterations with oncogenic potential, 
yet only a fraction of them will experience cancer transformation. This fact suggests that organisms 
evolved mechanisms to prevent oncogenic transformation, the so called anti-oncogenes or tumor 
suppressor genes. Tumor suppressors may avert cancer by preventing alterations, inducing cell death 
or a program of cell division arrest known as cellular senescence. This senescence has been 
experimentally modeled by enforcing the expression of oncogenes in primary cells. The astonishing 
outcome of these manipulations is that oncogenes trigger antiproliferative responses preventing 
progression to malignant transformation. These responses bring to an end-proliferation due to cell 
death or a permanent cell cycle arrest called senescence (Figure 2). On a general point of view, and 
although it remains to be validated in hepatocarcinogenesis, these results imply mechanisms of DNA 
damage in cells expressing oncogenes, that may be secondary to reactive oxygen species and/or some 
form of “oncogenic stress” that affect normal DNA replication. Interestingly, DNA damage signals 
persist in cells that escape from senescence and go ahead towards cancer transformation [25]. 
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Figure 2. The proposed molecular mechanisms of cellular senescence. Oncogenic stress 
result in DNA damages as double strand breaks (DSBs) that lead to activation of 
ATM/ATR kinases. This leads to stabilization of the Rad51 repair protein needed for DNA 
DSB repair. Besides DNA repair induction, cooperative action of ATM/ATR, ARF and 
Chk1/Chk2 and p53 is crucial for the induction of either apoptosis or cell cycle arrest and 
induction of senescence. Another possibility is that other factors such as reactive oxygen 
species (ROS) or other physical, chemical of viral agents could induce the accumulation of 
DNA damages or activate, by alternative mechanisms, the p15
INK4b/p16
INK4a cascade. All 
known senescence pathways converge at the level of activation of CDKIs (p15
INK4b, 
p16
INK4a and p21
Cip1) that keep the pRb protein under its active form. The pRb inhibits E2F 
and prevents the expression of growth-promoting genes for cell cycle exit. Furthermore, 
pRb recruits growth-promoting genes into a facultative chromatin structure for permanent 
silencing and growth arrest.  
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3.1. Senescence pathways as tumor suppressor mechanisms in chronic liver disease 
In healthy adult livers, hepatocytes are quiescent cells, being renewed slowly, approximately once a 
year. However, the liver has an extremely powerful regenerative capacity, as demonstrated 
experimentally in rodents, and as observed in patients with chronic liver diseases [26]. This 
regenerative capacity is due mostly to the ability of mature hepatocytes to proliferate in response to a 
diminution of the total liver mass either experimentally, or following exposure to viral and nonviral Viruses 2009, 1                                       
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hepatotoxic agents. In addition, the adult liver seems to harbor hepatocyte-progenitor cells (< 0.1% of 
total hepatocyte mass) that are able to restore liver hepatocyte populations [27]. However, hepatocytes 
do not have unlimited replicative capacity, due to the lack of telomerase activity that is needed to 
avoid telomere shortening during successive cell divisions. This is best exemplified by decreased 
hepatocyte proliferation in the cirrhosis stage of chronic liver diseases, providing in vivo evidence for 
the exhaustion of hepatocyte proliferation capacity [28].  
Senescence mechanisms in hepatocytes and in liver tissue are not well known. However, a limited 
number of in vitro studies with hepatocytes, as well as numerous descriptive in vivo studies in liver 
tissue provide sufficient evidence that hepatocytes can undergo senescence type changes. Limited 
proliferative capacity of somatic cells is controlled by replicative senescence. By contrast to primary 
hepatocytes which do not proliferate in culture, fetal hepatocytes display better proliferation capacity 
and can enter replicative senescence [29]. This is accompanied by progressive shortening of telomeres 
in a context of telomerase-free activity. In contrast to in vitro studies, in vivo senescence of human 
hepatocytes is better known. Replicative senescence displays a gradual increase from 10% in normal 
liver, to more than 80% in cirrhosis, being detected in 60% HCCs [30]. Telomere shortening during 
aging is slow and stabilizes at mid age in healthy liver, so that the loss of telomeric DNA does not 
reach a level to induce telomere dysfunction and DNA damage response (DDR). On the other hand, 
telomere loss is accelerated in chronic liver disease to reach lowest levels in the cirrhotic liver. 
Therefore, one plausible mechanism involved in cirrhosis is probably telomere-dependent senescence, 
the so-called replicative senescence [31]. 
Hepatocyte senescence that is observed in severe chronic liver diseases may also be induced by 
telomere-independent mechanisms, such as ROS-induced senescence (RIS) and oncogene-induced 
senescence (OIS). RIS and OIS are rare events under normal physiological conditions, but could more 
commonly occur in context of ROS overproduction and/or oncogenic signals activation, both leading 
to DDR and activation of the ATM/Chk/p53 pathway and, by alternative mechanisms, the 
p16
INK4a/pRb pathway. OIS is a DNA damage response triggered by DNA hyper-replication [32], and 
several oncogenic pathways – i.e. activated Ras, c-myc or Wnt/-catenin - have been shown as 
potentially involved in OIS in mammary cells or fibroblasts, but nothing is known about liver cell 
types [33-34]. As witness of DDR occurrence in chronic liver diseases, upregulation of DNA repair 
enzymes which may reflect increased DNA damages, has been reported in cirrhosis [35]. ROS 
production can be favored by the context of chronic liver injury with inflammation, cell death, 
oxidative stress as well as some of the etiological factors such as HCV and alcohol induce 
mitochondrial dysfunction [36]. Later on, we will describe the main oncogenic pathways found as 
activated in HCC and that might lead to OIS although this phenomenon of senescence-
induction/senescence-escape has not been clearly demonstrated so far in liver cells during 
hepatocarcinogenesis.  
3.2. Senescence-related aberrations in chronic liver disease and hepatocarcinogenesis 
The abrogation of DNA damage checkpoints could represent a selective advantage allowing clonal 
expansion of genetically altered hepatocytes at the stage of senescence (Figure 3). As stated earlier, the 
p16
INK4a/pRb and p53/p21
Cip1 pathways play crucial roles in senescence arrest as observed in different Viruses 2009, 1                                       
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in vitro and in vivo models [37]. Thus their invalidation could help the initiated cells to escape the 
senescent process and go ahead to genetic instability and cancerous transformation. Strikingly, 
etiologic factors per se of HCC, such the viral HBV X protein, have been shown to help cells to bypass 
OIS [38]. 
Figure 3. The proposed model of hepatocarcinogenesis. One or several types of liver cells 
(mature, hepatocytes, progenitor/stem cells) could support the multi-step process of 
accumulating genetic/epigenetic disorders leading to senescence, and subsequently 
bypassing senescence to reach cancer. Cirrhosis is a senescent state that could be induced 
by different factors such as ROS, oncogene activation and telomere shortening for 
instance. The senescent state is kept active by the p53/p21 and p16/pRb checkpoints. When 
these gatekeepers become inactive, the cell can bypass senescence, and re-enter cell cycle 
progression and DNA hyper-replication in a context of immortality, due to telomerase 
reactivation, and genetic insability. Thus, the cell is prone to acquire the last 
genetic/epigenetic hits necessary to get tumorigenicity and cancer stem cell capabilities.  
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The p53 pathway is a major tumor-suppressor pathway that: i) limits cell survival and proliferation 
(replicative senescence) in response to telomere shortening; ii) induces cell-cycle arrest in response to 
oncogene activation (OIS); and iii) protects genome integrity. The p53 pathway is affected at multiple 
levels in human HCC as follows: i) p53 mutations occur in aflatoxin-induced HCC (50%) and with 
lower frequency (20%-30%) in HCC not associated with aflatoxin; ii) microdeletions of p14
ARF occur 
in 15%-20% of human HCC but rarely in p53 mutant HCC; iii) increased Mdm2 expression has been 
observed in human HCC; iv) the vast majority of human HCC overexpresses gankyrin, which inhibits 
both the pRb and p53-checkpoint functions [39]. It seems likely that loss of p53 checkpoint function at 
the cirrhosis stage would lead to an expansion of hepatocytes with dysfunctional telomeres, 
chromosomal instability (CIN), and initiation of HCC. The p21
Cip1 gene, downstream target of p53, is 
accumulated in cirrhosis by comparison to normal liver tissues [40]. Although p21
Cip1 gene has not 
been found mutated in HCCs, its promoter is highly methylated in HCCs as compared to cirrhosis, Viruses 2009, 1                                       
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showing that p21
Cip1 is repressed in HCCs [41]. In addition to its effect on p53 checkpoint function, 
deletion of p14
ARF down-regulates expression of the p27 tumor suppressor [42].  
The p16/pRb checkpoint is another major pathway limiting cell proliferation in response to 
telomere shortening, DNA damage, and oncogene activation. In human HCC, retinoblastoma pathway 
alterations (p16
INK4a, p15
INK4b or RB1 genes) – i.e. mutation/deletion of RB1 and/or methylation of 
p16
INK4a, p15
INK4b promoters - are observed in more than 80% of cases, with repression of p16
INK4a by 
promoter methylation being the most frequent alteration [43], as well as gankyrin expression [39], 
indicating that the pRb checkpoint is dysfunctional in the vast majority of human HCCs. It is 
conceivable that an impairment of the pRb checkpoint would allow an expansion of hepatocytes with 
dysfunctional telomeres at the cirrhosis stage. In agreement with this assumption, p16
INK4a accumulates 
in cirrhosis by comparison to normal liver tissues, but p16
INK4a expression is diminished in 
premalignant liver tumors (small cell changes) and HCC [40].  
Activation of telomerase occurs during the transition from premalignant lesions to HCC. More than 
90% of human HCC show an activation of telomerase, which is the rate-limiting step for initiation of 
cell immortalization [44]. Experimental data from mice have shown that telomere shortening increases 
the initiation of liver tumors but telomerase deficiency limits the progression of early lesions toward 
macroscopic tumors [45]. A current hypothesis indicates that telomerase activation is necessary to 
limit telomere dysfunction and to prevent the accumulation of excessive levels of chromosomal 
instability and DNA damage that would impair tumor growth independent of p53 checkpoint function 
[46-47]. The molecular mechanisms involved in TERT suppression in somatic cells and its reactivation 
in cancer cells are poorly known. The integration of HBV DNA sequences into TERT gene provides 
evidence for a virus-induced deregulation of TERT expression, but this appears to rarely occur [48]. In 
addition, the viral X and PreS2 HBV proteins as well as the core HCV protein may upregulate 
telomerase activity [49]. Another hypothesis would be that HCC arise from stem/progenitor cell-like 
root cells that may already express TERT at sufficient levels to maintain telomere integrity. 
Experimentally, telomerase deletion limits the progression of p53-mutant HCCs with short telomeres 
[47]. These observations suggest that the aberrations affecting telomerase activity and senescence 
controlling genes such as p53 may cooperate during hepatocarcinogenesis. 
In summary, HCC is characterized by mutational inactivation of p53, a major player in DNA 
damage-induced senescence. In addition, p15
INK4b, p16
INK4a, p21
Cip1 CDKIs are often inactivated in 
this cancer mostly by epigenetic mechanisms involving promoter methylation. These changes may 
play a critical role in the bypass of senescence that is observed in most cirrhosis cases, allowing some 
initiated cells to escape senescence control and proliferate. Furthermore, it has been shown that Twist-
1 and Twist-2 proteins can switch pre-senescent mammary cells towards epithelio-mesenchymal 
transition (EMT) and senescence-bypassing rather than towards senescence [34,50-52]. Both proteins 
override oncogene-induced premature senescence by abrogating the p53 and pRb pathways, and this 
phenomenon remains to be confirmed in hepatocarcinogenesis. In the absence of telomerase activity 
such cells would probably not survive due to telomere loss. However, since more than 80% of HCCs 
display telomerase activity, it is highly likely that the telomerase reactivation, together with the 
inactivation of major CDKIs, plays a critical role in HCC development by conferring premalignant or 
malignant cells the ability to proliferate indefinitely. However, cellular immortality is not sufficient for Viruses 2009, 1                                       
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full malignancy. Thus, senescence-related aberrations that are observed in HCC cells, may confer a 
partial survival advantage that would need to be complemented by other genetic or epigenetic 
alterations to reach the cancerous phenotype. 
4. Activation of Oncogenic Pathways 
Hepatocarcinogenesis is multifactorial and various oncogenes, tumor-suppressor genes, growth 
factor genes and virologic factors are implicated [53]. Activation of oncogenic pathways in human 
HCC appears to be more heterogeneous compared with other cancer types. It remains largely unknown 
the exact sequence of the oncogenic pathways that could be activated during the different steps of 
hepatocarcinogenesis (Figure 3): i) at the pre-senescent step which leads from normal cells to 
senescent ones in cirrhosis; and/or ii) at the senescent steps which might allow the cell to bypass 
senescence, re-enter cell cycle progression and accumulate the next genetic/epigenetic hits required for 
acquisition of the cancerous phenotype; and/or iii) at the neoplastic step which allow cancerous cells to 
keep their cancerous phenotype which can evolve with time to aggressiveness, invasiveness and 
metastatic properties. Herein, we will focus on three major oncogenic pathways that might play a 
driving role in hepatocarcinogenesis - i.e. Ras, c-myc and Wnt/-catenin. These pathways have been 
shown as giving oncogenic stress in vitro in different models of carcinogenesis. Although they have 
been found activated in human HCC tisssues and/or their matched nontumorous counterparts by 
comparison to normal livers, experimental data are almost missing regarding their transforming 
properties on normal nontransformed liver cell types.  
4.1. Ras 
Proto-oncogenes of the ras family (H-ras, K-ras et N-ras) play a key role in transduction of the 
mitogenic signal linked to mitogen-activated protein kinases (MAPK). In humans, they can be 
activated by point mutation at codons 12, 13 and 61. In hepatocarcinogenesis, these mutations are 
uncommon and, when present, found at codon 12 for K-ras and H-ras, and at codon 61 for K-ras and 
N-ras [54]. In contrast, the p21-Ras protein is frequently expressed in cirrhosis and HCCs [55]. In 
vitro, ectopic expression of mutated ras is a strong oncogenic stress factor and leads frequently to 
cancerous transformation when the p53/p21
Cip1 and p16
INK4a/pRb checkpoints are inhibited and 
telomerase reactivated in mammary cell models [33]. However, few are known concerning liver cells.  
4.2. c-Myc 
The c-myc proto-oncogene stimulates a pattern of cellular gene expression by its regulatory 
elements and is involved in gene expression during cell growth and differentiation [56]. It has been 
shown to be important and acts as a driver oncogene in the process of experimental 
hepatocarcinogenesis since it is able to initiate and promote hepatocarcinogenesis in transgenic mice 
by giving rise sequentially to liver dysplasia and HCC [5,57-59]. However, its role in human 
hepatocarcinogenesis remains unclear. Previous studies have shown that c-myc is barely expressed in 
normal liver tissues [60]. By contrast, c-myc has been found overexpressed in most of the human 
hepatoma cell lines, and its repression by ribozyme or antisense therapy induces differentiation and Viruses 2009, 1                                       
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growth inhibition of these cells [61-62]. Also, in vivo studies have shown that c-myc expression may 
gradually increase from normal liver to chronic hepatitis, cirrhosis and HCC [63].  
Mechanisms of c-myc overexpression during human hepatocarcinogenesis are poorly understood, 
but might be related to amplification of the gene (40%-60% of HCCs, but rare in liver dysplasia) or 
hypomethylation of its regulatory sequences [64-65]. Speculation of c-myc overexpression as being an 
early event in the premalignant steps of human hepatocarcinogenesis may be of major importance 
since it has been found in more than 50% of human HCCs and their corresponding adjacent nontumor 
liver. Recent studies have shown that activation of c-myc is strongly associated with the malignant 
conversion of preneoplastic high grade dysplastic liver nodules in HCC [66]. A cytogenetic tumor 
progression model constructed by Poon and colleagues have determined that gains of 8q22-24 (bearing 
the c-myc allele) are among the earliest genomic events associated with HCC development [67]. 
Furthermore, it has experimentally been shown that c-myc is able to induce oncogenic stress in mouse 
embryonic fibroblasts [34], although it remains to be determined in normal human liver cells. Several 
observations have initially let hypothesize that, although c-myc triggering cellular growth may play a 
role in the premalignant steps during the process of malignant transformation (as reflected by its high 
mRNA steady state level in peritumor liver), it might not play a significant role in sustaining the 
growth of the tumor cells (as reflected by its lower mRNA steady state level in the corresponding 
tumor tissue) [68-69]. However, more recent data strengthen the role of c-MYC in maintenance of the 
cancerous phenotype since, although c-myc gene mRNA steady state level might not change or 
decrease in HCCs by comparison to the matched adjacent preneoplastic tissues, c-MYC activity can be 
enhanced by posttranscriptional modifications affecting the half-life of the protein. Phosphorylation of 
the Thr-58 residue in the Myc box I domain targets MYC for ubiquitination and consequent 
proteasosome-mediated degradation [70]. Although mutations of this region are frequently observed in 
Burkitt lymphomas and lead to stabilization of MYC, as well as to disruption of its pro-apoptotic 
function, these mutations have not been found in human HCC. A member of the COP9 signalosome – 
i.e. CSN5 - located at 8q13 locus, regulates activity of the ubiquitin ligase complex. It has recently 
been shown that CSN5 overexpression occurs at the early stages of hepatocarcinogenesis and shows a 
significant association with the presence of the c-MYC-regulated expression signature. These results 
are consistent with the notion that CSN5 plays an important role in liver cancer progression by a 
mechanism involving stabilization of the c-MYC protein and enhancement of its activity [66]. Another 
mechanism of increased c-MYC-activity could be its stabilizing interaction with HIF (hypoxia 
inducible factors) [71]. Finally, that transcriptional activity of c-MYC itself could be regulated by 
multiple pathways, including RAS/RAF/MAPK, JAK/STAT, and Wnt/-catenin signaling, which may 
result in a significant overlap between the c-MYC and other oncogenic pathways [72-75]. Thus it 
appears that c-MYC could be a central regulator of malignant transformation in early 
hepatocarcinogenesis.  
4.3. Wnt/-catenin 
The Wnt/-catenin pathway is regulated tightly during early liver development [76]. The -catenin 
molecule is an important multifactorial protein which is involved in cell-cell adhesion by strengthening 
the linkage between cadherin and -catenin to the actin cytoskeleton. Its soluble form can translocate Viruses 2009, 1                                       
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from cytosol to nucleus where it transactivates genes involved in cell fate during physiological 
homeostasis as well as for the setting of cancer properties. The Wnt/Frizzled signaling network 
controls activation of the canonical Wnt/-catenin signalling cascade and/or the noncanonical c-Jun N-
terminal kinase (JNK) and protein kinase C (PKC) [77].  
Although evidence is accumulating that alterations of the Wnt/-catenin pathway, due to or 
unrelated to -catenin gene mutation, is a common event in hepatocarcinogenesis [78-84], little is 
known concerning the noncanonical elements. The previous finding of inappropriate activation of the 
Wnt/-catenin pathway in hepatocarcinogenesis resulting from CTNNB1 gene mutations has provided 
clues toward understanding this process [78]. Different cohort studies of human HCC tissues have 
shown that activating mutations hitting the Wnt/-catenin pathways have been observed within the 
heterogeneous “end product” tumor bulk : the CTNNB1 gene encoding for the -catenin protein in 
10% to 30% of HCCs, the AXIN-1 gene in 7% to 9%, whereas APC gene mutations are exceptional 
[85-87]. However, the meaning of these mutations is questionable due to their absence in liver 
dysplasia, cirrhotic nodules or chronic hepatitis tissues, and due to their heterogeneity in HCC bulks 
since they concern only a fraction of tumor cells. Additionally, it appears that aberrant activation of the 
Wnt/-catenin pathway as manifested by cellular and nuclear accumulation of the -catenin protein 
occurs in a higher percentage of HCCs - i.e. 35% to 85% - while the Wnt/-catenin pathway gene 
mutations are absent [81-83]. More recently, it has been shown that, in absence of Wnt/-catenin 
pathway gene mutation, activation of the Wnt/-catenin pathway can occur by enhancement of the 
Wnt/Frizzled-mediated signalling. Indeed, it has been shown that binding of the WNT3 ligand on the 
FZD7 receptor can activate the canonical Wnt/-catenin pathway in human and rodent HCCs, 
enhancing the cancerous phenotype of cancerous human hepatoma cell lines. Interestingly, WNT3 
and/or FZD7 are overexpressed not only in 60% to 90% of human HCCs but also in 35-60% of the 
surrounding preneoplastic liver tissues, letting hypothesize that activation of the WNT3/FZD7-
mediated signalling might be an early event in hepatocarcinogenesis [79,80,88-90].  Additionally, 
down-regulation of the Wnt/Frizzled-mediated signaling per se has recently been shown as being an 
early key signal for senescence of primary human cells, suggesting at opposite that activation of 
Wnt/Frizzled-mediated signaling might force the presenescent cell to bypass the senescence program 
[91]. Thus it remains to be confirmed that activation of the Wnt/Frizzled-mediated signaling might be 
involved in the early steps of hepatocarcinogeneis through induction of cellular oncogenic stress and 
allowing to bypass senescence.  
5. Liver Inflammation and Hepatocarcinogenesis 
HCC arises most frequently in the setting of chronic liver inflammation due to viral infection, 
metabolic injury, toxic insults or autoimmune reactions. Liver cirrhosis itself is considered as the result 
of persistent liver damage and chronic inflammation. Cirrhosis also changes the microenvironment, 
which impacts on tumor formation. One of the hallmarks of cirrhosis is the activation of stellate cells, 
resulting in increased production of extracellular matrix proteins, cytokines, growth factors, and 
products of oxidative stress [92]. During recent years evidence has been accumulating to show that 
inflammation has an important role in initiation, promotion and progression of tumours, and that NF-
κB signalling is at the heart of the issue [93].  Viruses 2009, 1                                       
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NF-κB might be activated by the concerted action of cytokines or interleukins, such as TNF-α and 
IL-6, chemokines and viral proteins, which likely will promote cell survival of pre-cancerous 
hepatocytes [94]. Furthermore, cellular pathways such as EFGR-mediated cascade can activate NF-κB 
signalling leading to inhibition of c-Myc-induced apoptosis [95]. In the same view, NF-κB signalling 
can activate pro-survival factors such as Bcl-Xl and the XIAP caspase inhibitor [96-97]. Finally, the 
generation of pro-inflammatory cytokines and growth factors produced by tumour infiltrating 
macrophages, lymphocytes and other cell types in the tumour microenvironment provokes activation 
of NF-κB, protects against pro-apoptotic host immune defence mechanisms, influences cell 
differentiation and exert proangiogenic effects which stimulate the growth of cancer cells, tumour 
invasiveness and metastasis [98]. As a paradigm, the influence of inflammatory signalling on 
hepatocarcinogenesis can be context-dependent. Indeed, deletion of NF-κB-dependent inflammatory 
responses can enhance HCC formation in carcinogen-treated mice [99]. Similarly, deletion of NF-κB-
essential modulator/IκB kinase (NEMO/IKK), an activator of NF-κB, induces steatohepatitis and HCC 
in mice [100]. In contrast, inhibition of NF-κB impairs HCC progression in a mouse model of 
cholestatic hepatitis [101].  
Conversely, IL-6 production has been shown as occurring through MyD88-mediated Toll-like 
receptor (TLR) stimulation in rodent models, demonstrating the implication of the innate immune 
response in the hepatocarcinogenic process [102]. TLRs can be activated by nucleic acids in a context 
of viral infection, or by the damage-associated molecular patterns such as products of liver cell 
necrosis [103]. TLRs can thus act as finely tuned sensors of tissue damage fuelling inflammation and 
tissue reorganization following injury. Along these lines, the deletion of the suppressor of cytokine 
signalling-3 (SOCS3), a negative regulator of interleukin-6, promotes hepatitis-induced 
hepatocarcinogenesis in mice [104].  
6. Antiproliferative and Apoptosis Deficiency and Liver Cell Transformation 
The frequent inactivation of p53 in human HCC indicates that abrogation of p53-dependent 
apoptosis could promote hepatocarcinogenesis. In addition, p53-independent pathways can induce 
apoptosis in response to telomere dysfunction [47], although the role of impairments of p53-
independent apoptosis for hepatocarcinogenesis remains to be defined. It was shown that Hint2 (an 
apoptosis sensitizer acting at the mitochondria) is down-regulated in human HCC, correlating with 
poor prognosis [105]. The transforming growth factor- (TGF-) pathway is frequently activated at the 
cirrhosis stage and induces apoptosis by activating Smad3-mediated BCL2 repression [106]. Apoptosis 
resistance also could involve insulin-receptor signalling and activation of the Akt pathway [107]. 
The insulin-like growth factor 2 receptor (IGF2R) impairs cell proliferation by promoting 
degradation of the IGF2 mitogen and by activation of TGF- signalling [108]. Loss of heterozygosity 
in IGF2R locus is a frequent and early event in human hepatocarcinogenesis since occurring in more 
than 60% of dysplastic nodules and HCC [109]. Loss of IGF2R could cooperate with the IGF2 growth 
factor overexpression, which is a common feature in human HCCs. In addition, an abrogation of 
IGF2R could represent a selective advantage at the cirrhosis stage by impairing antiproliferative and 
pro-apoptotic signals induced by TGF-, which is overexpressed in cirrhosis. Interestingly, IGF2R is Viruses 2009, 1                                       
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located in the subtelomeric region of chromosome 6 in humans, indicating that telomere shortening 
could influence recombination rates and loss of heterozygosity of this locus [110]. 
Activation of the Akt signalling and impaired expression of phosphatase and tensin homolog 
(PTEN) (a negative regulator of Akt) have been reported in 40% to 60% of human HCC. Activation of 
the Akt pathway suppresses TGF--induced apoptosis and growth-inhibitory activity of 
CCAAT/enhancer binding protein . Both effects could promote tumor formation at the cirrhosis 
stage. Activation of the Akt pathway has been linked to an activation of -catenin signalling in 
intestinal stem cells [111-112]. 
7. Conclusion 
HCC is a major problem of public health, and a better understanding of hepatocarcinogenesis will 
help to identify pertinent molecular targets for innovative therapies. Although high output microarray 
analysis from tumor bulks have allowed to classify HCCs to predict outcome of patients, huge efforts 
are being done to identify liver cell types the most permissive to support the different 
genetic/epigenetic hits needed for cancerous transformation, and to accurately determine the sequence 
of these events. It has been clearly shown that cancer stem cells are indispensable for tumorigenicity, 
and much is being done to understand whether they come from transformation of normal liver stem 
cells or from de-differentiation of mature heptocytes that would have re-acquired stem cell properties. 
At preneoplastic steps, senescence has been shown as being a powerful anti-oncogenic mechanism in 
different cellular models supporting DNA stress secondary to oncogenic pathway activation, ROS 
production and/or telomere shortening for instance. Few is known in hepatocarcinogenesis at 
preneoplastic steps, but c-myc and Wnt/-catenin oncogenic pathways might be of relevance as well as 
ROS production and maybe viral factors. Cirrhosis could represent the senescent step where cell cycle 
arrest of hepatocytes is controlled by key checkpoints such as p53/p21
Cip1 and p16
INK4a/pRb. Their 
inactivation is a prerequisite for the pre-senescent cell to bypass senescence and to re-enter cell cycle 
progression, mechanisms that might be controlled by the Wnt signalling and the activity of Twist 
proteins, although it remains to be determined in hepatocarcinogenesis. Finally, abrogation of anti-
proliferative signals and of apoptosis, allow the post-senescent cell to become cancerous. However, 
one should keep in mind that tumors arise in a context of facilitating microenvironment (mesenchymal 
cells, immune response), and genetic/epigenetic hits necessary for cancerous phenotype in one single 
liver cell is not enough per se to allow tumor bulk to develop. All this angle of hepatocarcinogenesis 
has not been tackled in this paper. Additionally, of interest will be the chapter on interplays between 
HBV and HCV factors in hepatocarcinogenesis. 
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